MA55604B1 - Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra - Google Patents

Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra

Info

Publication number
MA55604B1
MA55604B1 MA55604A MA55604A MA55604B1 MA 55604 B1 MA55604 B1 MA 55604B1 MA 55604 A MA55604 A MA 55604A MA 55604 A MA55604 A MA 55604A MA 55604 B1 MA55604 B1 MA 55604B1
Authority
MA
Morocco
Prior art keywords
pdgfra
treatment
kit
related diseases
pyrrolotriazine derivatives
Prior art date
Application number
MA55604A
Other languages
English (en)
Other versions
MA55604A (fr
Inventor
Joseph L. Kim
Thomas A. DINEEN
Timothy Guzi
Original Assignee
Blueprint Medicines Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70416596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55604(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation
Publication of MA55604A publication Critical patent/MA55604A/fr
Publication of MA55604B1 publication Critical patent/MA55604B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés représentés par la formule I, des sels pharmaceutiques de ceux-ci, et/ou des solvates de l'un quelconque de ceux-ci, qui sont utiles pour le traitement de maladies et d'états liés aux KIT et PDGFRa mutants et qui présentent un profil ayant pour avantage de ne pas pénétrer dans le cerveau pour le traitement de maladies et d'états liés aux KIT et PDGFRa mutants. La présente invention concerne également des procédés de traitement de tumeurs stromales gastro-intestinales et de mastocytose systémique.
MA55604A 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra MA55604B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US201962930240P 2019-11-04 2019-11-04
EP20721083.2A EP3953357B1 (fr) 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra
PCT/US2020/027177 WO2020210293A1 (fr) 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra

Publications (2)

Publication Number Publication Date
MA55604A MA55604A (fr) 2022-02-16
MA55604B1 true MA55604B1 (fr) 2024-08-30

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55604A MA55604B1 (fr) 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra

Country Status (33)

Country Link
US (2) US10829493B2 (fr)
EP (2) EP4424312A3 (fr)
JP (2) JP7600140B2 (fr)
KR (1) KR102875260B1 (fr)
CN (1) CN113939515B (fr)
AU (1) AU2020272743B2 (fr)
BR (1) BR112021020441A2 (fr)
CA (1) CA3136802A1 (fr)
CL (1) CL2021002656A1 (fr)
CO (1) CO2021015113A2 (fr)
DK (1) DK3953357T3 (fr)
EC (1) ECSP21080096A (fr)
ES (1) ES2980811T3 (fr)
FI (1) FI3953357T3 (fr)
HR (1) HRP20240702T1 (fr)
HU (1) HUE067299T2 (fr)
IL (1) IL287168B2 (fr)
LT (1) LT3953357T (fr)
MA (1) MA55604B1 (fr)
MD (1) MD3953357T2 (fr)
MX (1) MX2021012469A (fr)
MY (1) MY209048A (fr)
PE (1) PE20212331A1 (fr)
PH (1) PH12021552568A1 (fr)
PL (1) PL3953357T3 (fr)
PT (1) PT3953357T (fr)
RS (1) RS65644B1 (fr)
SG (1) SG11202111244XA (fr)
SI (1) SI3953357T1 (fr)
SM (1) SMT202400229T1 (fr)
TW (1) TWI857043B (fr)
WO (1) WO2020210293A1 (fr)
ZA (1) ZA202108104B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782998B1 (fr) * 2018-04-16 2023-05-10 Shenzhen TargetRx, Inc. Composé de pyrrolotriazine substitué, composition pharmaceutique et utilisation associées
EP4424312A3 (fr) * 2019-04-12 2025-01-08 Blueprint Medicines Corporation Dérivés de pyrrolotriazine pour le traitement de maladies médiées par un kit et pdgfra
US20230391780A1 (en) * 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases
JP7828959B2 (ja) * 2020-10-14 2026-03-12 ブループリント メディシンズ コーポレイション Ｋｉｔおよびｐｄｇｆｒａ媒介疾患を処置するための組成物および方法
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
IL305611A (en) * 2021-03-03 2023-11-01 Blueprint Medicines Corp Synthetic methods and intermediates for the production of compounds for the treatment of PDGFRA-mediated diseases and kits
EP4305036A1 (fr) 2021-03-10 2024-01-17 Blueprint Medicines Corporation Formes salines et solides d'un inhibiteur de kinase
CN117794935A (zh) * 2021-03-10 2024-03-29 缆图药品公司 激酶抑制剂的盐和固体形式
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
KR20240115979A (ko) * 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
WO2024171143A1 (fr) 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Sels et formes solides d'elenestinib

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
JP2003511378A (ja) 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1497019B1 (fr) 2002-04-23 2015-05-20 Bristol-Myers Squibb Company Composes pyrrolo-triazine aniline utiles en tant qu'inhibiteurs de kinase
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
NZ541836A (en) 2003-02-27 2008-12-24 Palau Pharma Sa Pyrazolopyridine derivatives
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2005117909A2 (fr) 2004-04-23 2005-12-15 Exelixis, Inc. Modulateurs des proteines kinases et leurs methodes d'utilisation
EP1755607A2 (fr) 2004-04-29 2007-02-28 Pharmix Corporation Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PL1973910T3 (pl) 2006-01-27 2013-11-29 Shanghai hengrui pharmaceutical co ltd Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej
CN101511835B (zh) 2006-07-07 2013-11-27 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂
CN101808693A (zh) 2007-07-25 2010-08-18 百时美施贵宝公司 三嗪激酶抑制剂
JP2011515401A (ja) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
WO2010022055A2 (fr) 2008-08-20 2010-02-25 Amgen Inc. Inhibiteurs de canaux sodiques sensibles au potentiel
WO2010144345A1 (fr) 2009-06-08 2010-12-16 Abraxis Bioscience, Llc Dérivés de triazine et leurs applications thérapeutiques
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2013519732A (ja) 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
WO2012027495A1 (fr) 2010-08-27 2012-03-01 University Of The Pacific Analogues de pipérazinylpyrimidine en tant qu'inhibiteurs de protéine kinase
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
JP5955953B2 (ja) 2011-07-01 2016-07-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｌｋ１阻害剤としてのヒドロキシメチルアリール−置換ピロロトリアジン
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CN104981247A (zh) 2012-09-06 2015-10-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
WO2014160521A1 (fr) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Dérivés de pipérazine et leur utilisation comme modulateurs de kit
LT3057969T (lt) 2013-10-17 2018-07-10 Blueprint Medicines Corporation Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
US11040979B2 (en) * 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
EP3782998B1 (fr) 2018-04-16 2023-05-10 Shenzhen TargetRx, Inc. Composé de pyrrolotriazine substitué, composition pharmaceutique et utilisation associées
MA52489A (fr) 2018-05-04 2021-03-10 Inflazome Ltd Nouveaux composés
US20220010382A1 (en) 2018-11-12 2022-01-13 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
JP2022513925A (ja) 2018-12-20 2022-02-09 ファイザー・インク ＴＧＦβ阻害薬の新規多形体
EP4424312A3 (fr) * 2019-04-12 2025-01-08 Blueprint Medicines Corporation Dérivés de pyrrolotriazine pour le traitement de maladies médiées par un kit et pdgfra
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
US20230391780A1 (en) 2020-10-14 2023-12-07 Blueprint Medicines Corporation Compositions and methods for treating kit- and pdgfra-mediated diseases

Also Published As

Publication number Publication date
IL287168A (en) 2021-12-01
EP4424312A3 (fr) 2025-01-08
HRP20240702T1 (hr) 2024-08-16
KR20220025704A (ko) 2022-03-03
US10829493B2 (en) 2020-11-10
ECSP21080096A (es) 2022-02-25
US20220153748A1 (en) 2022-05-19
TWI857043B (zh) 2024-10-01
PE20212331A1 (es) 2021-12-14
AU2020272743B2 (en) 2025-10-16
AU2020272743A1 (en) 2021-11-11
WO2020210293A1 (fr) 2020-10-15
MD3953357T2 (ro) 2024-09-30
CN113939515A (zh) 2022-01-14
IL287168B1 (en) 2025-06-01
EP3953357B1 (fr) 2024-04-17
CA3136802A1 (fr) 2020-10-15
KR102875260B1 (ko) 2025-10-23
US12552795B2 (en) 2026-02-17
CO2021015113A2 (es) 2022-02-28
MA55604A (fr) 2022-02-16
TW202104231A (zh) 2021-02-01
PL3953357T3 (pl) 2024-09-02
US20200325141A1 (en) 2020-10-15
DK3953357T3 (en) 2024-06-10
SI3953357T1 (sl) 2024-08-30
JP7600140B2 (ja) 2024-12-16
IL287168B2 (en) 2025-10-01
MX2021012469A (es) 2022-01-18
CL2021002656A1 (es) 2022-08-26
ZA202108104B (en) 2024-02-28
CN113939515B (zh) 2024-06-18
JP2025029094A (ja) 2025-03-05
BR112021020441A2 (pt) 2021-12-14
EP4424312A2 (fr) 2024-09-04
FI3953357T3 (fi) 2024-07-15
MY209048A (en) 2025-06-18
ES2980811T3 (es) 2024-10-03
PT3953357T (pt) 2024-07-24
HUE067299T2 (hu) 2024-10-28
SG11202111244XA (en) 2021-11-29
LT3953357T (lt) 2024-07-25
PH12021552568A1 (en) 2022-07-04
SMT202400229T1 (it) 2024-07-09
RS65644B1 (sr) 2024-07-31
EP3953357A1 (fr) 2022-02-16
JP2022526850A (ja) 2022-05-26

Similar Documents

Publication Publication Date Title
EP4424312A3 (fr) Dérivés de pyrrolotriazine pour le traitement de maladies médiées par un kit et pdgfra
ZA202101449B (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
ZA202101960B (en) Protein tyrosine phosphatase inhibitors
PH12021552227A1 (en) Protein tyrosine phosphatase inhibitors
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
WO2022109396A8 (fr) Composés et leurs utilisations
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
BR9607240A (pt) Derivados de fenila trissubstituidos
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE463491T1 (de) Indolylmaleimid derivate
WO2024026484A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
ATE386742T1 (de) Imidazonaphthyridine
CA2534634A1 (fr) Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
WO2020165838A9 (fr) Procédés de traitement de la douleur de surface oculaire
EA200501881A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ ПИРРОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ HMG-CoA
BRPI0518690A2 (pt) tratamento de doenÇa inflamatària do intestino
EA200600316A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗУЕМЫЕ В НЕМ ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)
IL149280A0 (en) Methods, kits and compositions for using pyrrole derivatives
TW200742580A (en) Methods for treating nephrolithiasis
TW200612901A (en) Method and composition for treating gastrointestinal disorder
MA46462B1 (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret